|Series B, 8/10 |
Novartis Venture Fund
Anchor Therapeutics, Inc., a discovery and pre-clinical development-stage biopharmaceutical company, develops pharmaceutical candidates to address cancer, inflammation, metabolism, heart disease, and pain. The company develops Pepducin lipopeptide drug candidates, which are molecules that target the intracellular domains of G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling. Its Pepducin technology platform is used to develop lipopeptide allosteric modulators for intractable GPCR targets. The company was formerly known as Ascent Therapeutics, Inc. and changed its name to Anchor Therapeutics, Inc. in March 2010. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.